Has there been a shift in how the European courts approach preliminary injunctions?
by Dr Paul England and Christoph de Coster, LL.M. (UC Davis)
AI driven drug design
Unpacking the role of AI in bringing new drugs to market.
1 of 6 Insights
The EU torpedoes itself in cross-border patent disputes
Edison Open House Global Healthcare 2021 – key takeaways from our panel
by multiple authors
Will the UK government's COVID-19 dosing regime gamble pay off?
by Alison Dennis and Justyna Ostrowska
What the UK-EU Trade and Cooperation Agreement means for pharma and medical device companies
8+2+1 plus what? How UK data and market exclusivity rights will be affected from 1 January 2021
by Alison Dennis and Dr Paul England
SPC for ezetimibe/simvastatin considered invalid in preliminary relief proceedings
Targeted treatments – Part 3: the power of orphan drug protection
German Federal Court of Justice invalidates Truvada SPC
Targeted treatments – Part 1: Targeted treatments: patents for particular populations
CJEU ruling to liberalise parallel import in Poland